$36M in a Series C funding was raised from AEGEA Medical, a developer of medical devices used to treat abnormal uterine bleeding. The funding came from Alloy Ventures, Delphi Ventures, Covidien/Medtronic, BioMed Ventures and Solas Bioventures.
The firm said the funds go towards the submission of an application to the Food and Drug Administration (FDA), in order to market its procedure to treat abnormal uterine bleeding.